Tag: toxicity

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
onclive7

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relap...

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden.

Visit website
Immunotherapy Web Featured Images 123

Experimental safety switch reduces severity of CAR-T immunotherapy-related side ...

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
multiple3

How do I manage the risk of infection in patients treated with immunotherapies?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?

Visit website
Immunotherapy Web Featured Images 84

Scientists create ON-OFF switches to control CAR T cell activity

Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.

Visit website
vjhemonic18

Impact of age on ide-cel efficacy in the KarMMa trial

Jesus Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the updated results from KarMMa (NCT03361748), a study aiming to evaluate the efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in relapsed/refractory (R/R) multiple myeloma.

Visit website
onclive

Immunotherapy Expert Puts Fresh Focus on AEs

  Oct 15 2020 Tagged ICI, toxicity

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Visit website
cell1

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...

Human brain mural cells, essential for blood-brain barrier integrity, express CD19 and can then be potential off-tumor target for CD19-directed therapies, including CAR-T cells, suggesting a mechanism for associated neurotoxicity.
Visit website
ecancer

Fundamentals of nanoparticles in cancer immunotherapy and radiotherapy

Dr Selvaraj describes the future developments in this area, where next-generation nanoparticles could be developed to enhance the active targeting of tumour cells, and the compatibility with other anti-cancer therapies.

Visit website